

June 20, 2023

Company Anicom Holdings, Inc.  
 Representative Director Nobuaki Komori  
 (Securities Code: 8715 TSE PRIME)  
 Inquiries to Hiroshi Sato  
 Corporate Planning Department,  
 General Manager

## Monthly Management Parameters, May 2023

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Monthly Management Parameters, FY2023 (From April 1, 2023 to March 31, 2024)

	April	May	June	July	August	September
Net premiums written (previous year)	<b>4,346</b> JPYmn (4,053 JPYmn)	<b>4,594</b> JPYmn (4,332 JPYmn)	JPYmn (4,119 JPYmn)	JPYmn (4,085 JPYmn)	JPYmn (4,219 JPYmn)	JPYmn (4,253 JPYmn)
No. of policies in force (previous year)	<b>1,119,862</b> (-)	<b>1,126,210</b> (-)	(-)	(-)	(-)	(-)
Renewal rate (previous year)	<b>88.3%</b> (-)	<b>87.8</b> (-)	(-)	(-)	(-)	(-)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	<b>18,514</b> (17,080)	<b>18,945</b> (17,971)	(17,258)	(16,915)	(17,199)	(17,675)
No. of PARM hospitals* <sup>1</sup> (previous year)	<b>647</b> (443)	<b>654</b> (451)	(463)	(481)	(500)	(532)
No. of patents held* <sup>2</sup> (previous year)	<b>11</b> * <sup>3</sup> (-)	<b>11</b> (-)	(-)	(-)	(-)	(-)

	October	November	December	January	February	March
Net premiums written (previous year)	JPYmn (4,291 JPYmn)	JPYmn (4,173 JPYmn)	JPYmn (4,270 JPYmn)	JPYmn (4,400 JPYmn)	JPYmn (4,207 JPYmn)	JPYmn (4,388 JPYmn)
No. of policies in force (previous year)	(-)	(-)	(1,094,863)	(1,102,199)	(1,107,095)	(1,113,144)
Renewal rate (previous year)	(-)	(-)	% (88.0%)	% (88.0%)	% (88.3%)	% (88.4%)
No. of applicants of Doubutsu Kenkatsu (gut microbiota testing) (previous year)	(18,519)	(16,701)	(16,953)	(17,769)	(18,230)	(19,461)
No. of PARM hospitals* <sup>1</sup> (previous year)	(544)	(552)	(576)	(591)	(612)	(637)
No. of patents held* <sup>2</sup> (previous year)	(-)	(-)	(-)	(-)	(-)	(-)

\*1 This is a key figure regarding the progress of the regenerative medicine business.

The "Research and Development Partnership for Animal Regenerative Medicine (PARM)" is a non-profit mutual benefit corporation. Its purpose is to take advantage of industry-government-academia collaboration in order to standardize each process of cell therapy services for domestic animals (dogs and cats) and achieve the practical application of a system that makes it possible for veterinarians at all kinds of medical facilities to provide safe and effective cell therapy services.

\*2 We disclose the figure as a key figure related to the promotion of BioInsurTech using big data, with the aim of realizing a prevention-oriented company that prevents injuries and illnesses before they occur.

The "number of patent applications (cumulative total)" was disclosed until March 2023, but was changed to "number of patents held" from April 2023.

\*3 The number of patents held as of April 2023 was incorrect and has been corrected as follows.

	Before correction	After correction
No. of patents held* <sup>2</sup> (previous year)	<b><u>10</u></b> (-)	<b><u>11</u></b> (-)

(Reference) "Monthly Management Parameters" will be disclosed after middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December, and March.